Full-year results: operating profit increased by 13%
30 January - Sales increased by 8% in local currencies and by 6% in Danish kroner to 88.8 billion - sales growth driven by growth in sales of Levemir® and Victoza®. Lars Rebien Sørensen, CEO: “We are pleased with Novo Nordisk’s financial performance in 2014; a more challenging year than usual. Levemir® and Victoza® drove most of our sales growth, and our new long-acting insulin Tresiba® continues to perform well. 2015 will be an important year for us with the first launches of Saxenda® and Xultophy® as well as significant results from our late-stage development portfolio.”
Novo Nordisk Haemophilia Foundation 10 years
25 January -The Foundation (NNHF) is a grant-making non-profit organisation striving to improve access to care for people with haemophilia and allied bleeding disorders. This year, it’s 10 years since NNHF was founded with the vision that all people with haemophilia should receive adequate care and treatment wherever they live. The NNHF Council has so far approved 168 programmes in 63 countries in the developing world. The boys in the picture are 11-year-old Clemens who has von Willebrand Disease, 11-year-old Abbudulhi and Emmanuel at 12 who both have haemophilia A. Read more about haemophilia, the Foundation or see the short movie and see what the foundation is planning in connection with the anniversary
FDA approves Saxenda® for the treatment of obesity
23 December, 22 January- The US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. “Many people with obesity suffer from comorbidities. Saxenda® has the potential to help some of these people achieve and maintain a clinically significant weight loss and improve their weight-related comorbidities,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. The approval follows the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting on 11 September 2014, which voted 14–1 that the overall risk-benefit of Saxenda® was favourable and supported approval for chronic weight management. Novo Nordisk expects to launch Saxenda® in the US in the first half of 2015. On 22 January, Novo Nordisk received positive opinion for Saxenda® from the European regulatory authorities.
Read the full announcement on the FDA approval and Read the release on the EMA positive opinion
Tianjin and Shanghai join Cities Changing Diabetes on World Diabetes Day
14 November – On World Diabetes Day, the Chinese cities of Tianjin and Shanghai joined the Cities Changing Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in March 2014, followed by Copenhagen in Europe and Houston in the United States last week. Lars Rebien Sørensen, chief executive officer of Novo Nordisk welcomed the global leadership the two significant cities are showing in the fight against urban diabetes: “It is my hope that by working in partnership through Cities Changing Diabetes, we can complement and support the cities’ objective to reduce the growing type 2 diabetes burden and tackle this urgent problem”. See more
Insulin devices - the history
See the infographic on the history of Novo Nordisk's devices (pdf)
Maintaining glycaemic control
See all the health-related infographics on pinterest
Clinical Trial Transparency
1 March - Novo Nordisk has made it easier for external researchers to get access to clinical trial data. You may read about how we conduct our clinical trials, about volunteering to participate, how we disclose trial information to the public and how researchers can access clinical trial datasets.
Read more about clinical trials.
Annual report available online
B-roll and Video
30 January - New media b-roll material and videos on Executive Management and headquarters now available for download
Under the microscope
19 December - There's more to R&D than meets the eye. Read the stories in the latest issue of TBL Quarterly.
11 September - Read about the interaction between growth businesses and public-sector research and education. What challenges must be solved in order for research-based businesses to continue to grow in Denmark? Download the analysis in Danish or English.
Novo Nordisk Stories
Changing Diabetes in India
11 June - In India, there are not enough healthcare professionals to meet the needs of the 65 million people with diabetes. Partnerships can change this. Find out how (PDF)